Literature DB >> 19156873

Biochemical characterization of MLH3 missense mutations does not reveal an apparent role of MLH3 in Lynch syndrome.

Jianghua Ou1, Merete Rasmussen, Helga Westers, Sofie D Andersen, Paul O Jager, Krista A Kooi, Renée C Niessen, Bart J L Eggen, Finn C Nielsen, Jan H Kleibeuker, Rolf H Sijmons, Lene J Rasmussen, Robert M W Hofstra.   

Abstract

So far 18 MLH3 germline mutations/variants have been identified in familial colorectal cancer cases. Sixteen of these variants are amino acid substitutions of which the pathogenic nature is still unclear. These substitutions are known as unclassified variants or UVs. To clarify a possible role for eight of these MLH3 UVs identified in suspected Lynch syndrome patients, we performed several biochemical tests. We determined the protein expression and stability, protein localization and interaction of the mutant MLH3 proteins with wildtype MLH1. All eight MLH3 UVs gave protein expression levels comparable with wildtype MLH3. Furthermore, the UV-containing proteins, in contrast to previous studies, were all localized normally in the nucleus and they interacted normally with wildtype MLH1. Our different biochemical assays yielded no evidence that the eight MLH3 UVs tested are the cause of hereditary colorectal cancer, including Lynch syndrome.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19156873     DOI: 10.1002/gcc.20644

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  8 in total

Review 1.  Milestones of Lynch syndrome: 1895-2015.

Authors:  Henry T Lynch; Carrie L Snyder; Trudy G Shaw; Christopher D Heinen; Megan P Hitchins
Journal:  Nat Rev Cancer       Date:  2015-02-12       Impact factor: 60.716

2.  C-terminal fluorescent labeling impairs functionality of DNA mismatch repair proteins.

Authors:  Angela Brieger; Guido Plotz; Inga Hinrichsen; Sandra Passmann; Ronja Adam; Stefan Zeuzem
Journal:  PLoS One       Date:  2012-02-14       Impact factor: 3.240

3.  Mismatch repair gene MLH3 Pro844Leu and Thr942Ile polymorphisms and the susceptibility to cervical carcinoma and HPV infection: a case-control study in a Chinese population.

Authors:  Feng Ye; Qi Cheng; Jiajie Shen; Caiyun Zhou; Huaizeng Chen
Journal:  PLoS One       Date:  2014-04-23       Impact factor: 3.240

4.  Germline MLH1, MSH2 and MSH6 variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch Syndrome.

Authors:  Nayê Balzan Schneider; Tatiane Pastor; André Escremim de Paula; Maria Isabel Achatz; Ândrea Ribeiro Dos Santos; Fernanda Sales Luiz Vianna; Clévia Rosset; Manuela Pinheiro; Patricia Ashton-Prolla; Miguel Ângelo Martins Moreira; Edenir Inêz Palmero
Journal:  Cancer Med       Date:  2018-03-25       Impact factor: 4.452

Review 5.  Familial Colorectal Cancer Type X.

Authors:  Diana Bregner Zetner; Marie Luise Bisgaard
Journal:  Curr Genomics       Date:  2017-08       Impact factor: 2.236

6.  A Novel MLH1 Initiation Codon Mutation (c.3G>T) in a Large Chinese Lynch Syndrome Family with Different Onset Age and mRNA Expression Level.

Authors:  Yanni Zhang; Huishuang Chen; Zhiyu Peng; Santasree Banerjee; Wei Li; Zhaolong Zhao; Jianbin Sun; Jian Lv; Hui Huang; Ru Bai; Keke Lin; Zhongxin Li
Journal:  Biomed Res Int       Date:  2018-11-14       Impact factor: 3.411

7.  Mature microsatellites: mechanisms underlying dinucleotide microsatellite mutational biases in human cells.

Authors:  Beverly A Baptiste; Guruprasad Ananda; Noelle Strubczewski; Andrew Lutzkanin; Su Jen Khoo; Abhinaya Srikanth; Nari Kim; Kateryna D Makova; Maria M Krasilnikova; Kristin A Eckert
Journal:  G3 (Bethesda)       Date:  2013-03-01       Impact factor: 3.154

8.  Germline mutational profile of Chinese patients under 70 years old with colorectal cancer.

Authors:  Teng-Jia Jiang; Fang Wang; Ying-Nan Wang; Jia-Jia Hu; Pei-Rong Ding; Jun-Zhong Lin; Zhi-Zhong Pan; Gong Chen; Jian-Yong Shao; Rui-Hua Xu; Qi Zhao; Feng Wang
Journal:  Cancer Commun (Lond)       Date:  2020-09-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.